Top anti-rheumatic products based on global revenue in 2016 and 2022 (in million U.S. dollars)

Top worldwide anti-rheumatics by revenue 2016 and 2022 This statistic displays the top anti-rheumatics worldwide by revenue in 2016 and a projection for 2022. The drug Enbrel from Pfizer, Amgen, and Takeda is expected to generate domr 5.3 billion U.S. dollars in revenue in 2022. Anti-rheumatic drugs is used to treat and slow the progress of rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease that principlally attacks the joints but also impacts tissues and organs.
Anti-rheumatic products

Some of the top anti-rheumatic products in the world include J&J, Merck & Co., and Mitsubishi’s Remicade, which generated 8.1 billion U.S. dollars in revenue in 2016 and is expected to decrease to 2.7 billion U.S. dollars by 2022. This drug accounted for over 15 percent of the global market in 2016. Remicade is a trade name for infliximab, an antibody used in the treatment of autoimmune diseases. It is marketed under the name Remicade in the United States and cost between 19,000 and 22,000 per year for patients. Merck & Co. markets this product as Schering-Plough in other regions. Merck & Co. generated 1.7 billion U.S. dollars in their oncology segment in 2016. Remicade works by targeting tumor necrosis factor alpha and inhibiting its activity, but unlike similar rheumatic products like Humira, it is a monoclonal antibody.

Rheumatic diseases include conditions that affect the joints and connective tissue. Arthritis and gout are some of the more common types of this autoimmune disease. Osteoarthritis is one of the most common types of arthritis in the United States, it is characterized by the destruction of cartilage and bone. In Canada, 4.8 million adults over 15 reported that they had been diagnosed with arthritis.
Show more
Loading statistic...
Product (Company)20162022
Humira (AbbVie, Eisai)16,51515,901
Enbrel (Pfizer, Amgen, Takeda)9,2485,276
Otezla (Celgene)1,0173,673
Simponi (J&J, Merck)2,5113,582
Remicade (J&J, Merck, Mitsubishi)8,0702,742
Product (Company)20162022
Humira (AbbVie, Eisai)16,51515,901
Enbrel (Pfizer, Amgen, Takeda)9,2485,276
Otezla (Celgene)1,0173,673
Simponi (J&J, Merck)2,5113,582
Remicade (J&J, Merck, Mitsubishi)8,0702,742
Download Settings Share
Chart type
Datalabels
Share on Social Media
HTML code to embed chart as PNG (FAQ)
Download started
Please be patient - this may take a moment
Description Source More information
This statistic displays the top anti-rheumatics worldwide by revenue in 2016 and a projection for 2022. The drug Enbrel from Pfizer, Amgen, and Takeda is expected to generate domr 5.3 billion U.S. dollars in revenue in 2022. Anti-rheumatic drugs is used to treat and slow the progress of rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease that principlally attacks the joints but also impacts tissues and organs.
Anti-rheumatic products

Some of the top anti-rheumatic products in the world include J&J, Merck & Co., and Mitsubishi’s Remicade, which generated 8.1 billion U.S. dollars in revenue in 2016 and is expected to decrease to 2.7 billion U.S. dollars by 2022. This drug accounted for over 15 percent of the global market in 2016. Remicade is a trade name for infliximab, an antibody used in the treatment of autoimmune diseases. It is marketed under the name Remicade in the United States and cost between 19,000 and 22,000 per year for patients. Merck & Co. markets this product as Schering-Plough in other regions. Merck & Co. generated 1.7 billion U.S. dollars in their oncology segment in 2016. Remicade works by targeting tumor necrosis factor alpha and inhibiting its activity, but unlike similar rheumatic products like Humira, it is a monoclonal antibody.

Rheumatic diseases include conditions that affect the joints and connective tissue. Arthritis and gout are some of the more common types of this autoimmune disease. Osteoarthritis is one of the most common types of arthritis in the United States, it is characterized by the destruction of cartilage and bone. In Canada, 4.8 million adults over 15 reported that they had been diagnosed with arthritis.
Show more
Release date
June 2017
Region
Worldwide
Survey time period
as of May 2017
Supplementary notes
This statistic is ranked by the projected revenue in 2022.

More information

Statista Accounts: Access All Statistics. Starting from $588 / Year

Statistics on "Top pharmaceutical drugs"

  • Global overview
  • Select therapy classes - global
The most important statistics
  • U.S. overview
The most important statistics
  • Select therapy classes - U.S.

Related Studies: Available to Download in PDF or PPTX Format

Pharmaceutical brands: Enbrel (Amgen/Pfizer)

All Information
in one Presentation

Pharmaceutical brands: Enbrel (Amgen/Pfizer)

Everything On "Pharmaceutical brands: Enbrel (Amgen/Pfizer)" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista for Your Company: The Research and Analysis Tool

  • Product Film
  • Statistics
  • Downloads

Our Premium Statistics - facts for your business

Currently, Statista provides more than 1 million statistics.
93 percent (all Premium content) are exclusively accessible via our professional accounts.

Unlimited access

As a Statista Premium customer, you receive unlimited access to all statistics at all times. Including downloads of data in the most common formats (XLS, PDF & PNG). Create relevant and significant statistics in no time.

You are in good company

Further Content: Statistics, Studies, and Topic Pages

Our Business Solutions: Save Time and Money

only

$588*

per year
Your advantages
  • Full access to all our statistics
  • Download as XLS, PDF & PNG
  • Relevant data: complete source information
All functions of our platform illustrated face-to-face
  • Learn how Statista supports your company
  • Extensive tour across the whole portal
  • Personal guidance by our support team
The knowledge database for your company
  • All functions of the Premium Account
  • Access to dossiers, forecasts and studies
  • Access to our international database
  • Publishing rights and other exclusive functions

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar

We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.